Valve Science Center

A world-class research and education center for valvular heart disease, a life-threatening and debilitating condition when left untreated.

Join us in our mission to save the lives of patients with valvular heart disease!

For more information about valvular heart disease and current research studies, view the Valve Science Center patients page.
Learn about landmark achievements and publications and meet the team.
Support the mission and innovative work at the Valve Science Center and impact millions of lives.

Latest News

Heart Valve Awareness Day Event

Please join our free public education event to learn about: the public health epidemic of heart valve disease, how heart valve disease is diagnosed, the latest in heart valve disease research and treatments, and what you can do to help.

MHIF Valve Science Team Helps Improve Quality of Life for People Suffering From Tricuspid Regurgitation Symptoms

In early October, MHIF researcher Dr. Paul Sorajja, Roger L. and Lynn C. Headrick Family Chair for Valve Science Research, implanted the first 4TECH TriCinch™ System in the Midwest (the 23rd in the world) at Minneapolis Heart Institute® at Abbott Northwestern Hospital. MHIF is one of seven centers in the U.S. conducting the device’s Early Feasibility Study.

First in World TRILUMINATE Enrollment at MHIF

Minneapolis Heart Institute Foundation®Enrolls Patient in World’s First Pivotal Trial Testing New Approach for Repairing Leaky Tricuspid Heart Valves TRILUMINATE Pivotal trial is the randomized clinical trial...

MHIF at SCAI 2019

MHIF had several research physicians and staff attend the Society for Cardiovascular Angiography & Interventions 2019 Scientific Sessions in Las Vegas, NV in May. Check out some...

Sorajja in MedPage Today on Valve Center Definitions

Dr. Paul Sorajja, Roger L. and Lynn C. Headrick Family Chair for Valve Science Research at MHIF's Valve Science Center, was interviewed by MedPage Today recently regarding...

Landmark Achievements
  • First transcatheter mitral valve replacement in the U.S. Read more.
  • First-in-human therapy of severe mitral annular calcification. Read more.
  • First-in-human therapy of tricuspid regurgitation with the TriClip. Read more.
  • First-in-human therapy with the MyoCor device for treatment of mitral regurgitation. Read more.
  • First-in-human therapy of hypertrophic cardiomyopathy with MitraClip. Read more.
Read about the team of physicians, scholars and staff at the Valve Science Center.

Want to stay informed with Valve Science Center News? Join the mailing list!

5 + 1 =